Form 4: Emergent BioSolutions CFO Reports Routine Tax-Related Stock Disposition
Insider Transaction Report
Emergent BioSolutions' EVP and CFO, Richard S. Lindahl, reported the disposition of 2,733 shares of common stock to cover tax obligations related to restricted stock unit vesting.
Summary
- Richard S. Lindahl, Executive Vice President and Chief Financial Officer of Emergent BioSolutions Inc. (EBS), filed a Form 4 with the SEC.
- The filing details a transaction that occurred on June 8, 2025.
- Mr. Lindahl disposed of 2,733 shares of Emergent BioSolutions common stock at a price of $6.63 per share.
- This disposition was a 'tax withholding' transaction (Transaction Code F), meaning the shares were withheld by the issuer to satisfy tax obligations arising from the vesting and settlement of restricted stock units.
- Following this transaction, Mr. Lindahl beneficially owns 296,492 shares of Emergent BioSolutions common stock.
Sentiment
Score: 5
Explanation: The document reports a routine, tax-related insider transaction (disposition of shares to cover RSU vesting taxes). This is a neutral event and does not indicate any significant positive or negative operational or financial developments for the company.
Positives
- The transaction indicates the vesting and settlement of restricted stock units (RSUs) for the EVP and CFO, which is a standard component of executive compensation and a positive for the executive.
Negatives
- No direct negative implications from this routine tax-related disposition.
Risks
- NA
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Management Comments
- "Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units."
Industry Context
This Form 4 filing is a standard regulatory disclosure for insider transactions, common across all publicly traded companies, and does not provide specific industry context beyond the company's identity. It reflects a routine aspect of executive compensation in the biotechnology and pharmaceutical sectors.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- The disposition of shares was to the issuer (Emergent BioSolutions Inc.) to satisfy tax obligations related to the vesting of restricted stock units, which is a standard compensation-related transaction between an executive and the company.
Stakeholder Impact
- Shareholders: The transaction represents a minor, routine disposition of shares for tax purposes, which is a common occurrence with executive equity compensation and has negligible direct impact on share price or ownership structure.
- Employees: No direct impact on the broader employee base beyond the executive involved.
- Customers/Suppliers/Creditors: No direct impact on these stakeholders as the transaction is purely an internal compensation-related event.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 06/08/2025 | Date of transaction (disposition of shares for tax withholding). |
| 06/10/2025 | Date the Form 4 was signed by the reporting person. |
Recommendation
holdKeywords
Emergent BioSolutions, EBS, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, RSU, Tax Withholding, Richard S. Lindahl, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.